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Breast cancerCyclopeptide RA-V has potent anti-tumor and anti-angiogenic activities, but its potential anti-metastatic activity
is unknown. Cancer cells acquire invasive ability to degrade and adhere to extracellular matrix (ECM), allowing
them tomigrate to adjacent tissues and ultimatelymetastasize. Hence, the present study aimed to investigate the
effects of RA-V on cell adhesion, migration, invasion and matrix degradation, and its underlying mechanism in
two human breast cancer cell lines MCF-7 (ER-positive) and MDA-MB-231 (ER-negative). Our results demon-
strated that RA-V (12.5 nM) can signiﬁcantly inhibit breast cancer cell adhesion and migration via interfering
coﬁlin signaling and chemokine receptors involved in cell migration. RA-V reduced the expressions of vascular
intracellular adhesion molecule (VCAM), intracellular adhesion molecule (ICAM), focal adhesion kinase (FAK)
and integrins. The activities and expressions of matrix metalloproteinases (MMPs), tissue inhibitors of matrix
metalloproteinases (TIMPs) and urokinase-type of plasminogen activator (uPA) were also inhibited by RA-V.
Furthermore, RA-V inhibits the expressions of EGFR, PI3K/AKT and NF-κB signaling molecules, and reduces the
binding of β-estradiol to ER via affecting binding ability of ER in MCF-7 cells. RA-V inhibits breast cancer cell
migration, adhesion and ECM degradation in vitro, implying that RA-V is a potential anti-metastatic agent in
breast cancer, and likely acts via PI3K/AKT and NF-κB signaling pathways in both ER-positive and ER-negative
breast cancer cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the most frequent cancer diagnosed amongwomen,
accounting for 25% of all cancer cases. It is responsible for 12% of all
cancer cases [1]. Approximately 20% of patients with breast cancer at
early stage will develop metastasis [2]. Metastasis is responsible for
more than 90% breast cancer death [3]. Anthracyclines, Taxanes®
and 5-ﬂuorouracil are commonly used in clinic for the treatment of
metastatic breast cancer (MBC), but breast cancer recurrence and
chemotherapy-resistant MBC are frequently observed. Therefore, MBCthe inhibitory activities on cell
peptide RA-V in breast cancer
s an anti-breast cancer agent.
852 2603 5248.
htan@mail.kib.ac.cnis still incurable as the strategy of developing an anti-metastatic drug
lacks the full understanding of the entire metastatic process nowadays.
Plant-derived compounds are rich sources of clinically used anti-
cancer drugs, such as vinblastine, vincristine, irinotecan and paclitaxel
[4]. RA-V (deoxybouvardin), shown in Fig. 1A, a natural cyclopeptide
ﬁrst isolated from the roots of Bouvardia ternifolia [5] with a molecular
formula of C40H48N6O9. RA-V has also been isolated from the roots
from other related species such as, Rubia cordifolia [6,7] and Rubia
yunnanensis [8–10]. RA-V was shown to inhibit inﬂammation [10,11],
tumor growth [6], angiogenesis [12] and induce apoptosis [13].
DNA microarray can efﬁciently screen differential gene expression
by the gene expression proﬁling assay. Pathway analysis maps the
genes from the microarray data to pathways according to Biocarta and
Kegg databases. It ranks the pathways based on how relevant the path-
ways are to the genes in the microarray data, and gene ontology (GO)
analysis covers 3 domains, cellular component, molecular function and
biological process, so as to better describe gene product properties.
These analyses can be carried out to study the microarray data, and
Fig. 1. (A) Chemical structure of cyclopeptide RA-V. (B–E) Data of microarray analysis. (B) The heatmap of differential expressed genes in RA-V treated and untreated control samples
(n=3). Hierarchical cluster analysiswas carried out for all differential expressed genes (fold change≥2 or≤0.5; p value b 0.05) in RA-V-treated Hela cells, comparedwith the untreated
control. Each column represented one sample. Red colored columns indicated up-regulated genes while green colored columns indicated down-regulated genes. (C) Hierarchical cluster
analysis showed the differential expressions of tumor metastasis-related genes induced by RA-V. Each column represented one sample and each row represented one gene. The scale of
color intensitywas positively correlated to the fold change. (IGFBP6, insulin-like growth factor binding protein 6; ECM2, extracellularmatrix protein 2; ICAM4, intercellular adhesionmol-
ecule 4; TIMP4, tissue inhibitor of metalloproteinase 4; ICAM3, intercellular adhesion molecule 3; ICAM5, intercellular adhesion molecule 5; PLAU, urokinase-plasminogen activator;
ITGA2B, integrin, alpha 2b; LAMA3, laminin, alpha 3; ALDH3A2, aldehyde dehydrogenase 3 family, member A2; TP53, tumor protein p53; LAMB3, laminin, beta 3; ALDH5A1, aldehyde
dehydrogenase 5 family, member A1; ALDH3B1, aldehyde dehydrogenase 3 family, member B1; IGFLR1, IGF-like family receptor 1; COL1A1, collagen, type I, alpha 1; CFL2, coﬁlin 2;
MMP15, matrix metallopeptidase 15; ID1, inhibitor of DNA binding 1; IGSF8, immunoglobulin superfamily, member 8; ID3, inhibitor of DNA binding 3; TIMP3, tissue inhibitor of metal-
loproteinase 3; ALDH16A1, aldehyde dehydrogenase 16 family, member A1; MMP28, matrix metallopeptidase 28; IGSF3, immunoglobulin superfamily, member 3; LAMB2, laminin, beta
2; COL4A5, collagen, type IV, alpha 5; COL4A4, collagen, type IV, alpha 4; IGFL2, IGF-like familymember 2; TNC, tenascin C; IGF2BP1, insulin-like growth factor 2mRNA binding protein 1;
LAMA2, laminin, alpha 2; MMP7, matrix metallopeptidase 7; MMP19, matrix metallopeptidase 19; ITGB8, integrin, beta 8; ITGAM, integrin, alpha M; LAMB1, laminin, beta 1; r, laminin,
gamma 2). (D) RA-V induced cancer invasion and metastasis-associated GO categories. GO categories cover 3 domains, cellular component, molecular function and biological process.
Genes with differential expressions were analyzed and subjected to GO analysis in accordance with the SBC Analysis System. GO categories (p value b 0.05; Hit ≥ 5) were considered
to be signiﬁcant. ‘Hits’ was considered as the number of the differential expressed genes according to each GO category. (E) Table showed the top 5 signaling pathways involved in
Hela cells in response to RA-V. aThe number of the differential expressed genes in a pathway according to Biocarta and Kegg databases. bThe enrichment p value of the pathway as de-
termined by R-package Fisher's Exact Test.
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tivities of RA-V in cancer-related processes. In this study, microarray re-
sults revealed that RA-V was involved in suppressing cancer invasion
and metastasis; and hence, the anti-metastatic and anti-invasive activi-
ties of RA-V and its underlying mechanisms in breast cancer cells were
further examined.
Metastasis, an outgrowth of cancer cells in distant organs, is a com-
plex cascade of events. Proteolytic enzyme degradation of extracellular
matrix (ECM), cancer cell motility, proliferation and adhesion to ECMplay critical roles in cancer invasion and metastasis. Matrix metallopro-
teinases (MMPs) also play roles in proteolytic enzyme degradation of
ECM, and tissue inhibitor of metalloproteinases (TIMPs) and urokinase
plasminogen activator system such as urokinase-typeplasminogen acti-
vator (uPA) can tightly regulate the activity and level of MMPs. Many
studies show that MMPs are not only responsible for degrading ECM,
but also cell motility and adhesion [14] and metastasis [15]. MMP-1 is
the second most important gene mediated in breast cancer metastasis
to the lung and MMP-2 is also associated with breast cancer metastasis
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of patients suffering from breast cancer [17]. Overexpression of MMP-7
facilitates cancer invasion and also activation of MMP-2 and MMP-9
from their inactive forms in breast cancer cells [18]. TIMPs are capable
of inhibitingMMP activities [19]. uPA converts plasminogen into plasmin
which directly degrades ECM proteins and indirectly activates pro-MMPs
into active form of MMPs. Hence, increased expressions of MMPs, TIMPs
and uPA are associated with increased cancer progression and reduced
survival [20]. uPA can also induce cell migration. Constitutively active
PI3K regulates cell migration by uPA secretion via NF-κB activation in
breast cancer cells [21], and the regulation of cell migration in response
to uPA requires FAK [22]. In addition, FAK is involved in the activation
and secretion of MMP-2 and MMP-9 [23] as well as cell motility [24].
Once ECM has been degraded, it provides a path for cancer cells to
migrate. Chemokine receptors can mediate cancer cell motility and are
responsible for metastatic dissemination. Active chemokine receptors,
CXCR4 and CCR7 are expressed in high levels in breast cancer cells
and they are in response to their speciﬁc ligands CXCL12 and CXCL19
or CXCL21. Neutralizing anti-CXCR4 monoclonal antibody can inhibit
such chemotaxis in vitro and inhibit metastasis in vivo [25]. Chemokine
receptors expressed on breast cancer cells can direct these cells prefer-
entially to particular sites where their ligands are over expressed during
metastasis. Chemokine receptors also regulate cancer cell adhesion to
ECM and metastatic dissemination through integrin [26]. In addition,
coﬁlin signaling pathway is involved in actin polymerization and medi-
ates cell migration. Coﬁlin induces actin polymerization and direct can-
cer cell migration, and total coﬁlin is usually overexpressed in invasive
cancer cells [27]. Coﬁlin signaling pathway includes the involvement
of small G-proteins, RhoA and cell division cycle 42 (Cdc42), coﬁlin-
regulating kinase (ROCK1), phosphorylated coﬁlin and coﬁlin.
Cancer cell adhesion to the ECM can also facilitate cancer invasion.
Adhesion molecules such as vascular cellular adhesion molecule
(VCAM), intracellular adhesionmolecule (ICAM) are involved. Integrins
are αβ heterodimers and are cell adhesion receptors that regulate cell-
ECM adhesion and allow signal transduction across the membrane, as
well as link the ECM to actin cytoskeleton. Migrating cancer cells at
the leading edge adhere to the ECM and recruit actin cytoskeleton as
well as promote membrane protrusion. On the other hand, cells at the
rear edge detach from the ECM and disconnect to actin cytoskeleton.
Various subunits of integrin are responsible for the adhesion to ECM
components such as collagen, ﬁbronectin and laminin [28].
Breast cancer progression usually begins with hormone-sensitive,
non-metastatic cancer cells expressing estrogen receptor (ER) and sub-
sequently progressing to hormone-insensitive, invasive and metastatic
cancer cells with ER-negative phenotype. The response of the ER-
negative cancer cells with increasedmetastatic potential to current che-
motherapy or hormonal therapy is not compromising [29]. Therefore,
the development of a novel anti-metastatic drug with high efﬁcacy
and low toxicity in both ER-positive and ER-negative breast cancers is
urgently needed.
The present study aimed to investigate the anti-metastatic and anti-
invasive effects of RA-V on two human breast cancer cells. ER-positive
MCF-7 and ER-negative MDA-MB-231, representing slightly and highly
invasive cancer cells, respectively, were used in this study. Here, our
data demonstrated that RA-V inhibited breast cancer cell motility and
migration, cell proliferation, cell-ECM adhesion and ECM-associated
proteases including MMPs, TIMPs and uPA in both ER-positive MCF-7
and ER-negative MDA-MB-231 cells. RA-V was also demonstrated to
exert its anti-invasive effect via PI3K/AKT andNF-κB signalingpathways.
2. Materials and methods
2.1. Preparation of RA-V
RA-Vwas extracted and isolated from the root of R. yunnanensis. The
details of extraction and isolation procedures for RA-V have beenreported previously [10,12]. RA-V powder was dissolved in dimethyl
sulfoxide (DMSO) (Sigma, USA) at 10 mM as a stock solution. The
stock was stored at−20 °C and reconstituted in a medium prior to use.2.2. Cell culture
Human cervical cancer cells Hela and human breast cancer cells
MDA-MB-231 andMCF-7 were purchased from American Type Culture
Collection (ATCC, USA) during our study period (2008–2012). Hela cells
were maintained in Dulbecco's modiﬁed Eagle's medium, while MDA-
MB-231 and MCF-7 cells were maintained in RPMI medium 1640. The
media were supplemented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS) and 100 units/mL of penicillin–streptomycin. All the cul-
ture media, FBS and supplements were obtained from Life Technologies
(USA). The cells were incubated at 37 °C in a humidiﬁed atmosphere
of 5% CO2. All the cells obtained from ATCC were immediately
expanded and frozen down such that all cell lines could be restarted
every 3–4months from a frozen vial of the same batch of cells. Once re-
suscitated, cell lines were routinely authenticated through cell mor-
phology monitoring and growth curve analysis.2.3. Microarray and data analysis
Hela cells (6 × 105/mL) were seeded in 6-well plates (Corning, USA)
and incubated for 24 h. After another 24-h treatment with 100 nM of
RA-V or DMSO (0.001%) as a control, the cells were washed twice by
ice-cold PBS. Total RNA was extracted by using a TRIzol reagent (Life
Technologies, USA) according to the manufacturer's instructions. Its
quantiﬁcation and quality were assessed by spectrophotometry and
an Agilent 2100 Bioanalyzer (Agilent Technologies, USA) (Supplemen-
tary Fig. 1 and Table S1). Total RNA of the samples at 2 μg without deg-
radationwas ampliﬁed, labeled and hybridized. Gene expression proﬁle
was analyzed using the Agilent Whole Human Genome Oligo
Microarray kit, 4 × 44K (Agilent Technologies, USA), consisting of ap-
proximately 41,000 genes and transcripts. Treated and untreated sam-
ples in triplicate were used in the microarray assay which was carried
out by Shanghai Biochip Corporation (SBC) Limited (China). The exper-
imental data were analyzed using the SBC Analysis System, including
gene ontology (GO) and pathway enrichment analysis.2.4. Cytotoxicity MTT assay and [methyl-3H]-thymidine incorporation
assay
The cytotoxicity of RA-V on MDA-MB-231 and MCF-7 cells were
assessed using MTT assay. Cells (5 × 104/mL) were seeded in 96-well
ﬂat-bottom culture plate in 100 μL of medium and incubated overnight.
RA-V at various concentrations in 100 μL of medium was added to give
ﬁnal concentrations of 3.125 to 200 nM. A medium containing vehicle
solvent (0.5% (v/v) DMSO)was added to thewells as the untreated con-
trols. Microplate was then incubated for 24 or 48 h. Thirty microliters of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
solution (5 mg/mL) (Sigma, USA) was added and incubated for 3 h at
37 °C. Supernatants in each well were removed and 100 μL of DMSO
was added. Once the violet crystal was dissolved in DMSO, the plate
was read at 450 nm by a microplate reader (BioTek, USA). The change
in optical density was represented as a fold of untreated control.
The effect of RA-V on breast cancer cell proliferation was assessed
using [methyl-3H]-thymidine incorporation assay. Cells were seeded
as described above. After incubation for 18 or 42 h, 50 μL of
[methyl-3H]-thymidine solution (0.5 μCi) (PerkinElmer, USA) was
added and incubated for another 6 h at 37 °C. Plates were then placed
at−20 °C for at least 24 h. Once thawed, they were subjected to a scin-
tillation counter (Packard, USA)measurement [12]. The change in count
per minutes was represented as a fold of untreated control.
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Cell motility of MDA-MB-231 and MCF-7 cells was assessed using
scratch wound assay. Cells (1 × 105/mL) were seeded in a 24-well
plate and incubated overnight. The cells were starvedwith amedium
in 1% (v/v) FBS for 24 h. The cells were scraped with a cross by a
200 μL pipette tip in the middle of well. Each well contained 2
crosses. The crosses of each well were photographed under an
Olympus IX-71 microscope (Japan) at 0 h. A fresh medium with
3.125 to 25 nM of RA-V was added to the wells in triplicate and the
plate was incubated for 24 h. The crosses of each well were
photographed again at 24 h under a microscope. The percentages
(%) of open wound area were measured and the change in open
wound area (%) at 24 h from 0 h was calculated using the Tscratch
software [12]. Motility was determined by the decrease of the open
wound area.
2.6. Transwell migration assay
To assess the cell migration ability of MDA-MB-231 andMCF-7 cells,
transwell migration assay was performed using a Boyden chamber.
Cells (1.5 × 105/mL) in 200 μL of mediumwith 1% (v/v) FBS containing
RA-V at various concentrations were added to the upper chamber of
each transwell with 8 μm-pore size ﬁlter membrane (Corning, USA)
to give a ﬁnal concentration of RA-V at 6.25–25 nM in duplicate
transwells. A culture medium (500 μL) with 10% (v/v) FBS, as a
chemoattactant media, was added to the lower chamber. Transwells
were incubated for 4 h at 37 °C. After incubation, cells were ﬁxed
with methanol for 3 min and stained with hematoxylin for 5 min.
Cotton swab was used to scrap the cells on the top surface of the
ﬁlter membrane of the upper chamber gently. Stained ﬁlters were
photographed under an Olympus IX-71 microscope (Japan), and the
stained migrated cells were quantiﬁed by manual counting in a
double-blinded manner. Migration was determined by the number of
migrated cells.
2.7. Extracellular matrix cell (ECM) adhesion assay
To evaluate the effect of RA-V onMDA-MB-231 andMCF-7 cell-ECM
adhesion, an Extracellular Matrix Cell Adhesion Array kit (Millipore,
USA) was used. Each well of an eight-well strip was pre-coated with
one of the seven different human ECM proteins (collagen I, collagen II,
collagen IV, ﬁbronectin, laminin, tenascin or vitronectin) or BSA, as
negative control. The assay was carried out according to the procedures
recommended by the manufacturer. Brieﬂy, cells were added to pre-
coated wells treated with or without RA-V at 20 or 50 nM for 2 h.
After washing, bound cells were stained and dissolved in an extraction
buffer. The change in optical density was represented as a fold of un-
treated control.
2.8. Urokinase-type plasminogen activator (uPA) activity assay
The activity of uPA ofMDA-MB-231 andMCF-7 cells was assessed by
using uPA activity kit (Chemicon, Millipore, USA). Cells (1 × 105/mL)
were seeded in a plastic 24-well plate overnight. They were then
treated with RA-V (6.25–25 nM) in 0.5 mL culture medium with 1%
(v/v) FBS and incubated for 16, 24 or 48 h. A culturemediumwas col-
lected for the assay and centrifuged at 1000 ×g for 10 min.
Supernatants were collected and stored at −20 °C until use. The
assay was carried out according to the procedures recommended
by the manufacturer. Brieﬂy, a conditional medium diluted in assay
buffer provided was added to the wells containing uPA substrate
and incubated for 24 h at 37 °C. Secreted uPA from breast cancer
cells in the conditional medium would cleave a chromogenic sub-
strate to a colored uPA-containing sample, and the intensity of thecolored products was measured at 405 nm by a microplate reader
(BioTek, USA).
2.9. Gelatin zymography
The activities of MMP-2 and MMP-9 (gelatinases) of MDA-MB-
231 and MCF-7 cells were assessed by gelatin zymography. Cells
(1 × 105/mL) were seeded in a type I collagen-pre-coated 24-well
plate overnight. PBS was used to wash the wells twice to remove
remaining FBS. The cells were then treated with RA-V (6.25–12.5 nM)
in a culture medium replaced with 0.5 mL FBS-free culture medium
and incubated for 72 h. A culturemediumwas collected and centrifuged
at 1000 ×g for 10 min. Supernatants were subjected to gelatin
zymography. The supernatants were resolved by 10% SDS polyacryl-
amide gel polymerized with 0.1% gelatin. After electrophoresis, the
gels were washed with 2.5% Triton X-100 (Sigma, USA) for an hour
and incubated in a development buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 10 mM CaCl2) for 20 h at room temperature. The gels
were then stained with 0.25% coomassie blue R-250 (Sigma, USA) for
30 min and destained with 10% acetic acid in 5% ethanol until the
clear zones were observed. The activities of MMP-2 and MMP-9 were
observed as the clear zone, digested by MMP-2 and MMP-9 in the con-
ditional medium in the gels, captured by amolecular imager, ChemiDoc
XRS+ (Bio-Rad, USA). The clear zones were then quantiﬁed using
ImageJ (NIH, USA).
2.10. Western blot analysis
Protein expressions of MDA-MB-231 and MCF-7 cells were studied
by Western blotting. Cells (1 × 106) in a 7 mL culture medium
were seeded in a 100 mm culture dish and incubated overnight. Cells
were treated with RA-V (6.25, 12.5 or 25 nM) for various time-points
(4, 8, 16, 24 or 48 h). After incubation, the attached and ﬂoating cells
were harvested andwashed twicewith PBS. To obtainwhole cell lysate,
cell pellets were lysed with whole cell extraction buffer (2% SDS, 10%
glycerol, 625 mM Tris–HCl, pH 6.8) for 20 min with shaking on ice. To
obtain cytoplasmic cell lysate, cell pellets were lysedwith a cytoplasmic
cell extraction buffer (Thermo Scientiﬁc, USA). The samples were then
centrifuged at 14,000 ×g for 15 min at 4 °C. The supernatants were col-
lected and stored at−80 °C until used. Whole cell lysate and cytoplas-
mic cell lysate were subjected to Western blotting. The proteins were
heated at 95 °C for 5 min and subsequently resolved by 10% SDS poly-
acrylamide gel. The proteins in the gel were then transferred to
0.45 mm PVDF membrane (Millipore, USA) at 90 V for 90 min. The
blots were blocked with 5% non-fat dried milk in Tris-buffered saline
Tween 20 (TBST) (20 mM Tris–HCl, pH 7.6, 150 mM NaCl, 0.1%,
Tween-20). The blots were incubated with primary antibodies, beta-
actin (Sigma, USA), MMP1, MMP2, MMP7, MMP9, uPA, TIMP-1, ER,
ROCK1, pEGFR, EGFR (Abcam, USA), coﬁlin, p-coﬁlin, Cdc42, RhoA,
TIMP-2, PI3K, pPI3K, AKT, pAKT, FAK, NF-κB, pNF-κB, IκB and pIκB (Cell
Signalling, USA) overnight. The blots were then washed three times
with TBST and were incubated with secondary horseradish peroxidase-
conjugated anti-mouse or anti-rabbit antibodies (Invitrogen, USA) for
an hour. The signals on the blots were detected using an ECL solution
(GE Healthcare Life Sciences, Sweden), and were captured by a molecu-
lar imager, ChemiDoc XRS+ (Bio-Rad, USA). The signals were quantiﬁed
using ImageJ (NIH, USA).
2.11. Flow cytometry
Protein expressions of MDA-MB-231 and MCF-7 cells were studied
by ﬂow cytometry. Cells (1 × 106) in a 7mL culturemediumwere seed-
ed in a 100mmculture dish and incubated overnight. Cells were treated
with RA-V (6.25, 12.5 or 25 nM), LY294002 (20 μM, PI3K inhibitor) and
BAY11-7082 (5 μM, NF-κB inhibitor) (Sigma, USA) for 24 h. After incu-
bation, the attached and ﬂoating cells were harvested and washed
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jugated monoclonal antibodies, CD47b (integrin α2), CD47e (integrin
α5), CD47f (integrin α6), CD29 (integrin β1), CD184 (CXCR4), CD197
(CCR7) (Miltenyi Biotec, USA), VCAM-1, ICAM-1 (Abcam, USA) in
accordance with the manufacturer's speciﬁcations. Samples were
mixed well and incubated at 4 °C for 30 min in the dark, and they
were washed twice with PBS prior to analysis. Ten thousand events
were accumulated for each analysis by the ﬂow cytometer (Canto II,
BD Biosciences, USA).
2.12. Estrogen receptor (ER) binding assay
The binding of estrogen to ER inMCF-7 cellswas assessed by using ER
binding assay. Cells (1 × 106/mL) were seeded in a 100 mm culture dish
overnight. They were then treated with RA-V (50 or 200 nM) or tamox-
ifen (1000 nM) for 6 and 24 h. The attached and ﬂoating cells were
harvested and washed twice with PBS. To obtain cytoplasmic cell lysate,
cell pellets were lysed with a cytoplasmic cell extraction buffer (Thermo
Scientiﬁc, USA). The samples were then centrifuged at 14,000 ×g for
15 min at 4 °C. Each sample (300 μg/mL) was mixed with 17β-
estradiol (2 μCi) (PerkinElmer, USA) for 16 h at 4 °C. Charcoal solution
(Sigma, USA) was added to the mixture with gentle shaking for 2 h at
4 °C. They were centrifuged at 10,000 ×g for 10 min and supernatants
were subjected to ER binding assay by a scintillation counter (Packard,
USA).
2.13. Fibronectin adhesion assay
To determine whether the effect of RA-V on cell-ECM adhesion is
via PI3K signaling or integrin signaling, ﬁbronectin (Sigma, USA) at
20 μg/mL was coated on the wells of the 96-well plates (Corning, USA),
followed by a 2-hour incubation at 37 °C. MCF-7 cells (1.5 × 105/mL)
were added to the pre-coated wells treated with RA-V (25 nM) alone
or in combination with LY294002 (20 μg/mL) or integrin antagonist
(Gly-Arg-Gly-Asp-Ser) (20 μg/mL) (Abcam, USA) for 2 h. After washing,
bound cells were stained and dissolved in an extraction buffer (Millipore,
USA). The change in optical densitywas represented as a fold of untreated
control.
2.14. Statistical analysis
Data were expressed as mean + SD. Statistical analyses and signiﬁ-
cance were calculated by one-way ANOVA, Dunnett test and analyzed
using GraphPad PRISM software version 5.0 (GraphPad Software,
USA). In all comparisons, p b 0.05 was considered as statistically
signiﬁcant.
3. Results
3.1. RA-V altered gene expressions involved in cancer cell adhesion,
migration and invasion
To study the biological activities of RA-V in cancer, microarray anal-
ysis was carried out to investigate the change in gene expressions in
Hela cells treated with RA-V. Using the Agilent Whole Human Genome
OligoMicroarray, the gene expression proﬁling assay showed that 3449
geneswere found to bedifferentially expressedwhen treatedwith RA-V
at 100 nM (fold change ≥ 2 or ≤0.5; p b 0.05), compared with the un-
treated control. The heatmap of these genes was shown in Fig. 1B. Of
them, 1639 genes were up-regulated and 1810 genes were down-
regulated in RA-V-treated cells, compared with the untreated control.
Some genes involved in cell adhesion and cancer invasionwere affected
signiﬁcantly such as integrins, ECM-associated proteinases including
MMPs, uPA and TIMPs, ALDHs and ID-1 (Fig. 1C). GO analysis was per-
formed to understand the effects of RA-V in cancer cells in terms of
cellular component, molecular function and biological process andrevealed that RA-V strongly affected cell adhesion, cell motility, cell mo-
tion, ECM component binding and angiogenesis which were strongly
associated with cancer invasion and metastasis (Fig. 1D). Pathway en-
richment analysis was also carried out to further understand the effects
of RA-V on gene expressions in signaling pathways according to KEGG
and BioCarta databases. RA-V altered MAPK, p53, Wnt, MAPKK and
EGF signaling pathways (Fig. 1E) which are involved in cancer progres-
sion and metastasis, according to KEGG and BioCarta databases. These
microarray data strongly suggested that RA-Vwas involved in suppress-
ing cancer invasion and metastasis.
3.2. RA-V induced cytotoxicity and inhibited cell proliferation in breast
cancer cells
The cytotoxicity of RA-V on MDA-MB-231 and MCF-7 cells was de-
termined by MTT assay (Fig. 2A). IC50 values of MDA-MB-231 were
106.6 nM for 24 h and 39.2 nM for 48 h, and of MCF-7 cells were
114.9 nM for 24 h and 78.6 nM for 48 h. Hence, RA-V at up to 25 nM
was applied in the following culture assays as less than 70% cell viability
when treated with concentrations of RA-V higher than 25 nM for 24 h.
RA-V at 6.25 to 200 nM could signiﬁcantly inhibit cell proliferation in
MCF-7 cells when treated for 48 h (p b 0.001) (Fig. 2B). However,
such anti-proliferative effect of RA-V was not found when treated for
24 h only (data not shown).
3.3. RA-V reduced cell motility and migration in breast cancer cells
In the scratch wound assay, the open wound area (%) of the cells
treated with RA-V at 6.25 to 25 nM was signiﬁcantly greater than that
of the untreated (DMSO-treated) controls (Fig. 2C), indicating that
RA-V signiﬁcantly inhibited MDA-MB-231 and MCF-7 cell motility in a
dose-dependent manner. Untreated controls have clearly migrated to-
wards each other while the motility of both RA-V-treated breast cancer
cell lines was inhibited. Themigration of MDA-MB-231 andMCF-7 cells
was also signiﬁcantly inhibited in a dose-dependent manner when
treated with RA-V at 12.5 and 25 nM using transwell migration assay
(Fig. 2D). Cells have been migrated across the pore of the membrane
from the upper chamber of the transwell to the lower chamber.
The number of migrated cells was decreased when cells were treated
with RA-V, compared to the untreated controls, suggesting that RA-V
inhibited cancer cell migration.
3.4. RA-V reduced the expressions of chemokine receptors, CXCR4 and CCR7
in breast cancer cells
Chemokines can direct the migration and invasion of cancer cells,
which express corresponding chemokine receptors, leading to metasta-
sis to certain organs. In RA-V at 12.5 to 25 nM (Fig. 2E) they signiﬁcantly
and dose-dependently down-regulated the expressions of CCR7 and
CXCR4 on MCF-7 cell surface and CXCR4 on MDA-MB-231 cell surface,
determined by ﬂow cytometry. RA-V at 25 nM signiﬁcantly reduced
CCR7 expression on MDA-MB-231 and MCF-7 cells.
3.5. RA-V inhibited the expressions of coﬁlin signaling molecules
Coﬁlin signaling is involved in actin polymerization and mediates
cell migration. Results from Western blots revealed that RA-V at 6.25
to 25 nM signiﬁcantly reduced coﬁlin expression in MDA-MB-231 and
MCF-7 cells in a dose-dependent manner (Fig. 2F). The protein expres-
sions of Rho family of GTPases (Cdc42 and RhoA) and coﬁlin-regulating
kinase (ROCK1) which are involved in regulating coﬁlin activity were
signiﬁcantly inhibited by RA-V at 6.25 to 25 nM in a dose-dependent
manner. RA-V at 12.5 to 25 nM also dose-dependently increased the
expression of phosphorylated coﬁlin (inactive) in breast cancer cells.
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The ability of cancer cells to adhere to matrix proteins was
assessed by ECM adhesion assay. RA-V inhibited breast cancer celladhesion to extracellular matrix proteins (Fig. 3A). RA-V at 50 nM
signiﬁcantly decreased the adhesion of MDA-MB-231 cells to colla-
gen I to 70% of control. RA-V at 50 nM signiﬁcantly reduced MCF-7
cell adhesion to collagen I, collagen IV and ﬁbronectin to 82%, 73%
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laminin.
3.7. RA-V inhibited integrins, adhesion molecules, VCAM and ICAMs, and
focal adhesion kinase (FAK) in breast cancer cells
Integrin and adhesion molecules, VCAM and ICAMs are involved in
cell–cell or cell–matrix adhesion. Results from ﬂow cytometry revealed
that RA-V at 25 nM signiﬁcantly reduced all integrins α2, α5, α6 and β1
expressions on MDA-MB-231 cells, while at 12.5 to 25 nM, RA-V signif-
icantly inhibited all these integrin expressions onMCF-7 cells in a dose-
dependent manner (Fig. 3B and C). RA-V at 6.25 to 25 nM signiﬁcantly
inhibited VCAM-1 and ICAM-1 expressions on MDA-MB-231 and
MCF-7 cells in a dose-dependent manner (Fig. 3D and E). This was con-
sistent with the results from Western blotting (Fig. S2) which showed
that RA-V could reduce VCAM-1 and ICAM-1 expressions in MDA-MB-
231 and MCF-7 cells in a dose-dependent manner. FAK is a key protein
tyrosine kinase involved in various signaling pathways triggered by
integrin. FAK is responsible for cancer cell adhesion,migration and inva-
sion [30]. Results fromWestern blot (Fig. 3F) showed that RA-V at 12.5
to 25 nM could attenuate FAK expression in both MDA-MB-231 and
MCF-7 cells treated for 24 h (Fig. 3G).
3.8. RA-V attenuated MMP-9 and uPA activities in breast cancer cells
MMPs and uPA (plasminogen activator) are ECM-associated prote-
ases involved in matrix degradation. Gelatin zymography revealed the
activities of MMP-9 and MMP-2 (gelatinases) secreted by MDA-MB-
231 cells which were seeded on a collagen I-pre-coated well plate and
treated with RA-V at 6.25 to 12.5 nM for 72 h (Fig. 4A). Collagen I was
used as a substrate to stimulate the secretion ofMMP-9 by breast cancer
cells. The activity of MMP-9, but not MMP-2, secreted by MDA-MB-231
cells was signiﬁcantly inhibited by RA-V at 6.25 to 12.5 in a dose-
dependent manner (Fig. 4B). However, the activities of both MMP-2
and MMP-9 secreted by MCF-7 cells were negligible as no clear zones
were observed in the stained gel (data not shown).
RA-V at 6.25 to 25 nM signiﬁcantly inhibited the activity of uPA se-
creted by MDA-MB-231 cells incubated with RA-V for 24 h (Fig. 4C).
The activity of uPA secreted by MCF-7 cells was also signiﬁcantly
inhibited when cancer cells treated with RA-V at 6.25 to 25 nM for
48 h (Fig. 4C), but not 24 h (data not shown).
3.9. RA-V down-regulated uPA, TIMP and MMP protein expressions
To determine the effects of RA-V on the expressions of the ECM-
associated proteinases, MMPs, MMP-1, MMP-2, MMP-7 and MMP-9
protein expressions were studied in breast cancer cells using Western
blot (Fig. 4D). RA-V at 25 nM signiﬁcantly inhibited MMP-1, MMP-7
and MMP-9 expressions in MDA-MB-231 cells at 24 h (Fig. 4E). RA-V
could reduce MMP-2 expressions in MDA-MB-231 although there was
no signiﬁcant difference. RA-V at 25 nM also signiﬁcantly inhibited
MMP-1, MMP-2, MMP-7 and MMP-9 expressions in MCF-7 cells atFig. 2. Inhibitory effects of RA-V on breast cancer cellmotility andmigration. (A) Cytotoxic effec
48 h byMTT assay. Data were expressed as themean fold of untreated control (mean± SD of 3
MDA-MB-231 andMCF-7 cells treated with RA-V at 6.25 to 200 nM for 48 h by [methyl-3H]-thy
3.125 nM to 25 nM for 24 h in scratch wound assay. Representative photographs showing wou
after incubation. The histogram showed the effects of RA-V at 3.125 to 25 nM on cancer cell mo
percentage of the change in open wound area at 24-h compared with those at 0 h (mean + SD
were treated with RA-V at 6.25 to 25 nM for 4 h in transwell migration assay. Representative p
treated controls on the lower side of the membrane after incubation. The histogram showed th
after incubation. After incubation, the cells that have migrated to the lower chambers were sta
(E) Flow cytometric analysis showed the chemokine receptor expressions onMDA-MB-231 and
FITC- or PE-conjugated antibodies. The histograms showed the quantiﬁed results of the protein
dent experiments). Statistical differences were determined by one-way ANOVA, followed
(F) Representative blots showed the effect of RA-V on coﬁlin signaling molecules in MDA-MB-
16 h, respectively. The histograms showed the quantiﬁed results of the expressions of the tar
expressed as fold of control (mean + SD of 3–4 independent experiments).48 h, but not at 24 h (data not shown). RA-V at 12.–25 nM signiﬁcantly
inhibited MMP-1 expression in MCF-7 cells and inhibited MMP-9 and
MMP-7 expressions inMDA-MB-231 cells in a dose-dependentmanner.
Being a plasminogen activator and an MMP inhibitor respectively,
uPA, TIMP-1 and TIMP-2 play a role in matrix degradation. Therefore,
the inhibitory effects of RA-V on their expressions have been studied.
RA-V at 6.25–25 nM inhibited TIMP-1 and TIMP-2 protein expressions
in MDA-MB-231 for 24 h and MCF-7 cells for 48 h (Fig. 4E) in a dose-
dependent manner. RA-V at 12.5–25 nM also signiﬁcantly and dose-
dependently inhibited uPA expressions in both breast cancer cell lines.
Taken together with the results of the uPA activity assay, RA-V inhibited
both the expressions as well as the activities of uPA proteins in MCF-7
and MDA-MB-231 cells.
3.10. RA-V inhibited the phosphorylation of EGFR in response to EGF in
breast cancer cells
The results from pathway enrichment analysis (Fig. 1E) demonstrat-
ed that RA-V alters gene expressions in EGF signaling pathway in cancer
cells. In addition, RA-V at 25 nM signiﬁcantly inhibits the phosphoryla-
tion of cytoplasmic EGFR as well as reduces the expression of cytoplas-
mic EGFR at protein level in MDA-MB-231 and MCF-7 cells when
treated for 8 h in the presence of EGF (Fig. 5A). The expression of cyto-
plasmic pEGFR is lower than that of cytoplasmic EGFR in RA-V-treated
MDA-MB-231.
3.11. RA-V inhibited the protein expressions of AKT, PI3K and pPI3K in
breast cancer cells
PI3K/AKT signaling is involved in cell survival and cell proliferation.
PI3K is shown to associate with breast cancer cell migration., RA-V at
12.5 to 25 nM signiﬁcantly reduced the pPI3K, PI3K and AKT levels in
MDA-MB-231 cells at 8 h and in MCF-7 cells at 16 h in a dose-
dependent manner (Fig. 5C and D). However, RA-V did not reduce the
phosphorylation of AKT in both cancer cell lines.
3.12. RA-V reduced the phosphorylation of IκBα and NF-κB in breast cancer
cells
To determine the effects of RA-V on NF-κB signaling transduction,
the phosphorylation of both IκBα and NF-κB in the whole cell extracts
of breast cancer cells were studied. RA-V at 25 nM signiﬁcantly reduced
the phosphorylation of NF-κB while the total levels of NF-κB were un-
changed in both MDA-MB-231 and MCF-7 cells (Fig. 5E and F). RA-V
at 25 nM also signiﬁcantly inhibited the phosphorylation of IκB in
both cell lines.
3.13. RA-V exhibited its anti-invasive properties via PI3K and NF-κB
signaling pathways in breast cancer cells
LY294002 (PI3K inhibitor) at 20 μMsigniﬁcantly reducedmost of the
expressions of integrins (Fig. 6A), speciﬁcally integrinα5 (p b 0.01) andts of RA-V onMDA-MB-231 andMCF-7 cells treatedwith RA-V at 3.125 to 200 nM for 24 or
independent experiments with 5 replicates each). (B) Anti-proliferative effects of RA-V on
midine incorporation assay. (C) MDA-MB-231 andMCF-7 cells were treated with RA-V at
nd-inducedmotility of cancer cells treated with RA-V at 25 nM and the untreated controls
tility, determined by the openwound area after incubation. Results were expressed as the
of 3 independent experiments with 6 replicates each). (D) MDA-MB-231 andMCF-7 cells
hotographs showing migrated cancer cells treated with RA-V at 25 nM as well as the un-
e effects of RA-V on cancer cell migration, as determined by the number of migrated cells
ined and they were counted (mean + SD of 3 independent experiments with duplicates).
MCF-7 cells. Cancer cellswere treatedwith RA-Vat 6.25 to 25nMfor 24h, and stainedwith
expressions on cancer cells, and expressed as fold of control (mean+ SD of 3–4 indepen-
by Dunnett test, with *p b 0.05, **p b 0.01, ***p b 0.001 against untreated control.
231 and MCF-7 cells. Cells were treated with or without RA-V at 6.25 to 25 nM for 8 and
get proteins, which were normalized with corresponding β-actin protein expression and
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BAY11-7082 (NF-κB inhibitor) at 5 μM could only signiﬁcantly inhibit
integrins α2 and α5 in MDA-MB-231 cells, and integrin β1 in MCF-7
cells (p b 0.05), suggesting that the effects of RA-V on reduced integrin
expressions in breast cancer cells were mostly via PI3K/AKT signaling
rather than NF-κB signaling. LY294002 also signiﬁcantly inhibited theFig. 3. Inhibitory effect of RA-V on breast cancer cell adhesion. (A) Inhibitory effect on MDA-MB
treatedwith RA-V (20 nMand 50nM) in ECMprotein-precoatedwells for 2 h. Resultswere expr
in duplicates). Flow cytometric analysis showed the inhibitory effect of RA-V (25 nM) on (B) int
were treated with RA-V at 6.25 to 25 nM for 24 h, and stained with FITC- or PE-conjugated a
(E) VCAM-1 and ICAM-1 expressions using ﬂow cytometry, and expressed as fold of control (m
in MDA-MB-231 and MCF-7 cells. MDA-MB-231 and MCF-7 cells were treated with or withou
(G) The histograms showed the quantiﬁed results of Western blot analysis, which were norm
(mean + SD of 3–4 independent experiments). Statistical differences were determined by on
untreated control.expression of chemokine receptors, CXCR4 and CCR7 in MDA-MB-231
and CCR7 in MCF-7 cells (Fig. 6B). On the other hand, reduced expres-
sion of CXCR4 but not CCR7 was found in both cell lines in the presence
of BAY11-7082 (p b 0.05). Furthermore, as shown in Fig. 6C, a signiﬁcant
reduction in expressions of VCAM-1 and ICAM-1 were found in MCF-7
cells treated with LY294002 or BAY11-7082 (p b 0.01). Besides,-231 andMCF-7 cell adhesion to ECM proteins by ECM-adhesion assay. Cancer cells were
essed as themean fold of the untreated control (mean+SDof 3 independent experiments
egrin expressions (D) VCAM-1 and ICAM-1 onMDA-MB-231 andMCF-7 cells. Cancer cells
ntibodies. The histograms showed the quantiﬁed results of (C) integrin expressions and
ean + SD of 3–4 independent experiments). (F) Representative blots of FAK expression
t RA-V at 6.25 nM to 25 nM for 24 h. Whole cell lysate was subjected to Western blotting.
alized with corresponding β-actin protein expression and expressed as fold of control
e-way ANOVA, followed by Dunnett test, with *p b 0.05, **p b 0.01, ***p b 0.001 against
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could signiﬁcantly inhibit ICAM-1 in MDA-MB-231 cells (p b 0.001).
LY294002 reduced ICAM-1 expression to 75% in MDA-MB-231 cells, al-
though no signiﬁcant difference was found. These ﬁndings suggested
that RA-V inhibited cancer invasion via PI3K and NF-κB signaling.
In order to further determine whether RA-V exerts its anti-invasive
effect via PI3K signaling, the effect of single and combined use of RA-V
(25 nM) and LY294002 (PI3K inhibitor) (20 μM) on cell migration, ad-
hesion and proliferation were further investigated. Both RA-V and
LY294002 signiﬁcantly reduced MCF-7 cell migration to 46% and 45%,
respectively (Fig. 6D), and reduced MCF-7 cell-ﬁbronectin adhesion
to 72% and 82%, respectively (Fig. 6F). In addition, both RA-V and
LY294002 attenuated 50% of the proliferation of MCF-7 cells (Fig. 6F).
There was no signiﬁcant difference between the RA-V treated group
and the combined group of RA-V and LY294002 in MCF-7 cells accord-
ing to Bonferroni's multiple comparison test. These results demonstrate
that the inhibitory effects of RA-V on MCF-7 cell migration, adhesion
and proliferation are competitive with LY294002, and RA-V exerts its
anti-invasive activities via PI3K signaling in hormone-responsiveness
MCF-7 cells. For MDA-MB-231 cells, both RA-V and LY294002
signiﬁcantly inhibited cell migration to 28% and 44%, respectively
(Fig. 6D). There was no signiﬁcant difference between the RA-V treated
group and the combined group of RA-V and LY294002, according to
Bonferroni's multiple comparison test. As the anti-adhesive effect ofFig. 4. Inhibitory effect of RA-V onmatrix degradation. (A) Inhibitory effects of RA-VonMMP-2a
I collagen-precoated wells for 72 h. Collected condition media were subjected to gelatin zymo
stained gelatin gel. (B) Quantiﬁed analysis showed the effects of RA-V on MMP-2 and MMP
MMP-9 on the gel. Results were expressed as the percentage of the controls (mean+ SD of 3 ind
of uPA secreted by breast cancer cells. MDA-MB-231 and MCF-7 cells seeded on a plastic 24-w
expressed as the mean fold of the untreated controls (mean + SD of 3 independent experime
MB-231 andMCF-7 cells. MDA-MB-231 andMCF-7 cellswere treatedwith orwithout RA-V at 6
blotting. (E) The histograms showed the quantiﬁed results of the expressions of the ECM-associa
expressed as fold of control (mean+ SD of 3 independent experiments). Statistical differences
***p b 0.001 against untreated control.RA-V on MCF-7 cells is more compromised than MDA-MB-231 cells
(Fig. 3A), only the underlyingmechanism of RA-V onMCF-7 cell-ECM ad-
hesion to ﬁbronectin was investigated. In addition, RA-V and LY294002
reduced cell proliferation to 75% and 64%, respectively (Fig. 6F). The com-
bined group was signiﬁcantly lowered as compared to RA-V-treated
group, but not LY294002-treated group. Therefore, such a signiﬁcant de-
crease might be due to the inhibitory effect of LY294002, instead of
their additive/synergistic effect. These results also revealed that the in-
hibitory effects of RA-V on MDA-MB-231 cell migration and prolifera-
tion were competitive with LY294002 (Fig. 6D−E), and RA-V exerted
its anti-invasive activities via PI3K signaling in hormone-irresponsive
MDA-MB-231 cells.3.14. RA-V inhibit MCF-7 cell-ﬁbronectin adhesion via integrin binding
Integrin antagonist (Gly-Arg-Gly-Asp-Ser) consists of the Arg-Gly-
Asp sequence that is the attachment site for a variety of known integrins.
Integrin antagonist (Gly-Arg-Gly-Asp-Ser) reducedMCF-7 cell adhesion
to ﬁbronectin, as integrins onMCF-7 cells can adhere to the integrin an-
tagonist, instead of its ligands such as ﬁbronectin. The ﬁbronectin adhe-
sion assay showed that RA-V, integrin antagonist or RA-V plus integrin
antagonist signiﬁcantly reduced MCF-7 cell-ﬁbronectin adhesion to the
same extent, which were about 75% (p b 0.001) (Fig. 6F). These resultsndMMP-9activities ofMDA-MB-231 cells, treatedwith RA-V at 6.25nMto12.5 nM in type
graphy. Representative photographs showed the activities of MMP-2 and MMP-9 on the
-9 activities of MDA-MB-231 cells, represented by the digested gelatin by MMP-2 and
ependent experimentswith duplicates each). (C) Inhibitory effects of RA-V on the activity
ell plate were treated with RA-V at 6.25–25 nM for 24 and 48 h, respectively. Data were
nts with duplicates each); (D) Representative blots of ECM-associated proteases in MDA-
.25 nM to 25 nM for 24h and 48h, respectively.Whole cell lysatewas subjected toWestern
ted proteases, whichwere normalizedwith corresponding β-actin protein expression and
were determined by one-way ANOVA, followed by Dunnett test, with *p b 0.05, **p b 0.01,
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attenuating its integrin binding.
3.15. RA-V increased the ER expression of ER-positive breast cancer cells,
MCF-7
In order to determine whether RA-V exerted its anti-cancer effects
via ER, the binding of estrogen to ER and the expression of ER in ER-
positive MCF-7 cells were investigated. Tamoxifen is an antagonist of
estrogen receptor, and can inhibit estrogen-induced cell growth in an
ER-dependent manner. Tamoxifen could also signiﬁcantly increase ER
expression (data not shown). RA-V at 12.5 to 25 nM also increased ER
expression of MCF-7 in a dose-dependentmanner (Fig. 7A). In addition,
β-estradiol can trigger estrogen receptor endocytosis in ER-positive
cells. Reduced cytoplasmic ER expression was found in MCF-7 cells in
response to β-estradiol at 10 nM, suggesting that β-estradiol could
induce receptor endocytosis inMCF-7 cells (Fig. 7B). The effect on estro-
gen receptor endocytosis was reversed in the presence of RA-V
(p b 0.05) or tamoxifen. Increased ER expression in cytoplasm revealed
that RA-V might inhibit receptor endocytosis induced by β-estradiol.
To further investigate whether increased ER expression is associated
with ER binding for β-estradiol, ER binding assay and Western blotting
were carried out. Both reduced ER binding and increased cytoplasmic
ER expression of MCF-7 cells pre-treated with RA-V (50 or 200 nM) or
tamoxifen (1000 nM) for 6 h or 24 h were found (Fig. 7C). However,
when non-pre-treated cytoplasmic ER proteins mixed with β-estradiol
and RA-V, no reduced ER binding to estrogen was found (data not
shown). On the other hand, themixture of non-pre-treated cytoplasmicFig. 5. The effect of RA-V on various signaling pathways in breast cancer cells. Representative b
(E) NF-κB signaling inMDA-MB-231 andMCF-7 cells. MDA-MB-231 andMCF-7 cells were treat
(C–F) whole cell lysate was subjected toWestern blotting. The histograms showed the quantiﬁ
(F) NF-κB signaling pathwayswhichwere normalizedwith corresponding β-actin protein expr
tistical differences were determined by one-way ANOVA, followed by Dunnett test, with *p b 0ER proteins, β-estradiol and tamoxifen showed reduced ER binding to
estrogen. This strongly suggests that RA-V does not competewith estro-
gen for the ER in a manner similar to tamoxifen. Instead, RA-V reduces
the binding of β-estradiol to ER via affecting binding ability of ER
in MCF-7 cells. Our results demonstrated that RA-V reduces the
binding of β-estradiol to ER evenwith increased cytoplasmic ER expres-
sion, suggesting that RA-V triggers receptor endocytosis and inhibits
estrogen-induced biological activity (Fig. 7D).
4. Discussion
Cancer cells need to acquire invasive abilities so as to metastasize.
These processes require cancer cell proliferation, adhesion, migration
and ECM proteolysis, and thus suppressing these steps may result in
inhibiting tumor invasion. The cyclopeptide RA-V, isolated from the
roots of R. yunnanensis, has been previously demonstrated as an anti-
tumor and anti-angiogenic agent [6,7,10–13]. However, few studies
have extensively studied the underlying mechanisms of the anti-
migratory, anti-adhesive, anti-invasive and anti-proliferative effects of
RA-V. Our microarray data strongly suggested that RA-V is a potential
anti-metastatic agent as it could alter cancer cell adhesion, cell motility,
cell motion, ECM component binding and angiogenesis which are in-
volved in metastatic processes. Furthermore, GO analysis showed that
RA-V could down-regulate some of the metastasis-related genes such
as ICAM, MMPs and uPA, as well as interfere MAPK, p53, Wnt, MAPKK
and EGF signaling pathways (p b 0.05) which play a critical role in can-
cer metastasis. In the present study, we demonstrated for the ﬁrst time
that RA-V inhibited breast cancer cell invasion by suppressing cancerlots of the expressions of the signaling molecules involved in (A) EGFR, (C) PI3K/AKT and
edwith orwithout RA-V at 6.25 to 25 nM for 8 and 16 h, respectively. (A–B) Cytoplasmic or
ed results of the expressions of the target proteins involved in (B) EGFR, (D) PI3K/AKT and
ession and expressed as fold of control (mean+ SD of 3–4 independent experiments). Sta-
.05, **p b 0.01, ***p b 0.001 against untreated control.
Fig. 6. The anti-invasive effects of RA-V via PI3K and NK-κB signaling. Cancer cells were treated with LY294002 at 20 μM or BAY11-7082 at 5 μM for 24 h, and stained with FITC- or PE-
conjugated antibodies. Flow cytometric analysis showed the effects of LY294002 and BAY11-7082 on (A) integrin subunits, (B) chemokine receptors, and (C) adhesion molecules,
VCAM-1 and ICAM-1 on MDA-MB-231 and MCF-7 cells. The histograms showed the quantiﬁed results of the protein expressions on cancer cells, and expressed as fold of control
(mean + SD of three to four independent experiments). The effects of single and combined application of RA-V (25 nM) and LY294002 (20 μg/mL) on (D) MDA-MB-231 and MCF-7
cell migration for 24 h by transwell migration assay, and (E) MDA-MB-231 and MCF-7 cell proliferation for 48 h by [methyl-3H]-thymidine incorporation assay. (F) The effects of single
and combined application of RA-V (25 nM), LY294002 (20 μg/mL) or integrin antagonist (20 μg/mL) onMCF-7 cell adhesion to ﬁbronectin for 2 h by ﬁbronectin adhesion assay. (D–F) The
histograms showed the quantiﬁed results expressed as fold of control (mean+SDof 3–4 independent experiments). Statistical differenceswere determinedby one-wayANOVA, followed
by Dunnett test, with *p b 0.05, **p b 0.01, ***p b 0.001, ###p b 0.001 against untreated control.
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and NF-κB signaling pathways. RA-V was also shown to inhibit the pro-
tein expressions and activities of ECM-associated proteinases involved
in ECM degradation.
RA-V has been shown previously to induce signiﬁcant cytotoxicity
on a variety of human cancer cells and endothelial cells [10,12,13].
Our study also showed that RA-V exerted signiﬁcant cytotoxicity on
MDA-MB-231 and MCF-7 cells (Fig. 2A). RA-V was previously demon-
strated to sensitize breast cancer cells to mitochondria-mediated
apoptosis through inhibiting PDK1-AKT with high RA-V concentrations
i.e. 100–1000 nM [13]. However, in this study, lower concentrations of
RA-V were applied in different cell culture assays because our approach
was to inhibit cancer cell invasive ability at a low concentration to avoid
inducing high cytotoxicity.
The migratory ability of cancer cells allows them to migrate to adja-
cent tissues and ultimatelymetastasize. Results from the scratchwound
assay and transwell migration assay showed that RA-V signiﬁcantly in-
creased the change in the open wound area, uncovered by migrating
cells, and reduced the number of migrated cells through the transwell
membrane. The single and combined use of RA-V and LY294002 were
also shown to inhibit breast cancer cell migration to a similar extent in
transwell migration assay, revealing that RA-V reduced breast cancer
cell migration via PI3K signaling. In addition, RA-V reduced the expres-
sions of CXCR4 and CCR7, which are expressed in high levels in MDA-
MB-231 and MCF-7 cells. RA-V potentially affected via PI3K and NF-κB
signaling pathways. RA-V inhibited the expressions of coﬁlin signaling
molecules which are involved in actin polymerization aswell as cell mi-
gration. Activation of chemokine receptors such as CXCR4 can alsoinduce actin polymerization and mediate migration, adhesion as well
as integrin activation [31]. Thesemay contribute to the inhibitory effects
of RA-V on cell migration.
ECMnot only acts as a barrier to invasion, but also is involved in cell-
ECM interactions during invasion. Our ECM adhesion assay data re-
vealed that RA-V signiﬁcantly inhibited cell adhesion of MDA-MB-231
to collagen I, and of MCF-7 to collagen I, collagen IV and ﬁbronectin
which are the major components of the ECM. RA-V reduced adhesion
to collagen II and laminin in MCF-7 cells. Integrins on MCF-7 cells can
adhere to the integrin antagonist instead of its ligands. Our ﬁbronectin
adhesion assay demonstrated that RA-V and RA-V plus integrin antago-
nist reduced MCF-7 cell-ﬁbronectin adhesion to the same extent, and
RA-V and RA-V plus LY294002 also attenuated such adhesion to the
same extent (Fig. 6F). These results demonstrated the anti-adhesive
effect of RA-V on MCF-7 cells underlying integrin binding and PI3K sig-
naling. Furthermore, RA-V was shown to reduce FAK, integrin subunits,
VCAM and ICAM expressions in both cell lines, in turn it might also con-
tribute to the attenuation of cell adhesion to ECM proteins, and hence
inhibited invasion.
Differential responses of RA-V on the adhesion of MDA-MB-231 and
MCF-7 cells to ECM proteins may be due to their integrin expressions.
MCF-7 and MDA-MB-231 cells have different levels of α and β integrin
subunits. Our results showed that much higher levels of α2, α5 and α6,
and a slightly higher level of β1 were found in MDA-MB-231 cells as
compared with MCF-7. Consistent with Morini's group, they reported
that MDA-MB-231 cells have high levels of α5 and α6 integrin subunits
while MCF-7 cells have a moderate level of α5 and low levels of α6.
MCF-7 cells also express reduced levels of α2 subunits compared with
Fig. 7. (A) The effect of RA-V on estrogen receptor (ER) protein expression inMCF-7 cells byWestern blot analyses. MCF-7 cells were treatedwith RA-V at 6.25 to 25 nM for 4 h.Whole cell
lysate was subjected toWestern blotting, and representative blots of MCF-7 cells were shown. (B) The effect of RA-V on ER protein expression inMCF-7 cells byWestern blot analyses in
response toβ-estradiol.MCF-7 cellswere treatedwith RA-V (25nM) or tamoxifen (10 nMor1000nM) for 4 h in the presenceofβ-estradiol at 10nM. Cytoplasmic cell lysatewas subjected
to Western blotting, and representative blots of MCF-7 cells were shown. (C–D) MCF-7 cells treated with (50 or 200 nM) or tamoxifen (1000 nM) for 6 or 24 h. Cytoplasmic cell lysates
were subjected to (C) ER binding assay and (D)Westernblotting. For ERbinding assay, cytoplasmic cell lysates at 300 μg/mLweremixedwith radioactiveβ-estradiol (2 μCi) for 16 h. For all
Western blotting, the histogram showed the quantiﬁed results of the expression of proteins, whichwere normalizedwith corresponding β-actin protein expression and expressed as fold
of control treated with estradiol only (mean + SD of 3–4 independent experiments). Statistical differences were determined by one-way ANOVA, followed by Dunnett test, *p b 0.05,
**p b 0.01, ***p b 0.001 against control treated with estradiol only. Statistical differences between untreated control and control treated with estradiol only by unpaired t-test, with
##p b 0.01. (E) Schematic diagram of the proposed underlying mechanisms of the anti-metastatic effect of RA-V.
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lar adhesion to different ECM proteins. For example, α2β1 and α5β1 are
responsible for cellular adhesion to collagen andﬁbronectin, respective-
ly [28]. Therefore, the differential inhibitory effects of RA-V on cellular
adhesion to various ECM componentsmay be due to the differential ex-
pression levels of α and β heterodimers between MDA-MB-231 and
MCF-7 cells. In addition, up-regulating β1 integrins of cancer cells
could lead to increased cell adhesion and invasion through collagen IV
[33] and ﬁbronectin [34]. RA-V at 25 nM signiﬁcantly reduced β1
integrin expression on MCF-7 cells to a higher extent than that on
MDA-MB-231 cells (decreased to 46% in MCF-7; decreased to 78% in
MDA-MB-231) (Fig. 3C). This may explain why RA-V is slightly less ef-
fective to inhibit MDA-MB-231 cells to collagen IV and ﬁbronectin.
Apart from inhibiting cancer cell adhesion and migration through
the ECM, attenuating the expression and activity of ECM-associated pro-
teinases including MMPs, uPA and TIMPs is also responsible for
inhibiting ECM degradation and cancer cell invasion. Results from
Western blot and gelatin zymography revealed that RA-V could reduce
MMP-1, MMP-2, MMP-7 and MMP-9 protein expressions as well as
MMP-9 activity in breast cancer cells. The activity of MMPs is tightly
controlled by a plasminogen activator, uPA and MMP inhibitors,
TIMPs. High level of uPA is associatedwith reduced relapse-free survival
and overall survival, breast cancer metastasis and a poor prognosis of
breast cancer [35,36]. RA-V reduced the protein expression and activity
of uPA involved in proteolytic enzyme degradation in breast cancer
cells. As TIMPs play a role in inhibiting MMP activity, it is expected
that low levels of TIMPs in cancer cells are in favor of cancer progression,
invasion and metastasis [37]. On the contrary, this potential anti-
metastatic agent, RA-V was shown to reduce the expressions of TIMP-
1 and TIMP-2 in breast cancer cells (Fig. 4D–E). Such controversy may
be due to themultifunction of TIMP-1 and TIMP-2. TIMPs can also stim-
ulate cell proliferation, inhibit apoptosis, and modulate angiogenesis
[38]. A preponderance of research has shown that high levels of TIMP-
1 [39] and TIMP-2 [40] proteins are signiﬁcantly correlated and associ-
atedwith poor outcome such as higher tumor stage and reduced overall
survival rate of patients suffering from breast cancer and breast cancer
metastasis. In short, cancer metastasis can be facilitated by the imbal-
ance between MMPs and TIMPs rather than reduction of TIMP level
alone. Reduced activity and protein expressions of ECM-associated pro-
teinases, uPA and TIMPs of breast cancer cells by RA-Vmay therefore re-
sult in reduced cancer cell invasion and metastasis.
Our results from ﬂow cytometry revealed that the expressions of
migration-related and adhesion-related molecules including chemo-
kine receptors, integrins and adhesion molecules (VCAM-1 and ICAM-
1) are the downstream molecules of PI3K and NF-κB signaling path-
ways. Constitutively active PI3K and NF-κB signaling pathways are usu-
ally found in highly invasive cancer cells such as MDA-MB-231 [41].
Blocking PI3K/AKT and NF-κB signaling pathways can result in de-
creased breast cancer cell migration [42] and the activity of ECM-
associated proteases including uPA and MMP-9 [21]. RA-V was shown
to inhibit PI3K/AKT and NF-κB activations, so it might exert its anti-
metastatic effects through these signaling pathways. The RA-V treated
group and the combined group of RA-V and LY294002 exerted similar
anti-migratory, anti-adhesive and anti-proliferative effects on MDA-
MB-231 and MCF-7 cells, further conﬁrming that RA-V exerts its anti-
migration, anti-adhesion and anti-proliferation via PI3K signaling
(Fig. 6D–F).
ER-positive breast cancer is responsive to anti-estrogen therapy and
usually has a better clinical outcome than an ER-negative one. However,
hormonal therapy is not applicable to ER-negative breast cancer, so it is
important to identify an anti-metastatic agent that is capable of inhibiting
ER-negative tumor growth in ER-independentmanner. As RA-V could in-
duce anti-invasive effect on two breast cancer cell lines, ER-positive poor-
ly invasive MCF-7 and ER-negative highly invasive MDA-MB-231 cells, it
gave rise to a question that whether RA-V exerted its inhibitory effects
via ER-dependent and/or ER-independent pathways. RA-V could inhibitcell migration, adhesion and invasion of ER-negative MDA-MB-231
cells, suggesting that RA-V could exert its inhibitory effects via ER-
independent pathway. Beta-estradiol can trigger ER endocytosis in
MCF-7 cells, resulting in decreased cytoplasmic ER expressions. RA-V
could increase cytoplasmic ER expression in MCF-7 cells after a short
period of time following RA-V treatment, implying that it was able to
inhibit receptor endocytosis. RA-V reduced the binding of β-estradiol
to ER via affecting binding ability of ER instead of competing with
β-estradiol to ER. Our results strongly suggest that the inhibitory effect
of RA-V on cell migration, adhesion and matrix degradation is ER-
independent. The inhibitory effects of RA-V on cell migration, adhesion
and matrix degradation in ER-positive MCF-7 and ER-negative MDA-
MB-231 cells are in similar extent, implying that the inhibitory effect
of RA-V in MCF-7 cells on cell migration, adhesion and matrix degrada-
tion is ER-independent. A lower dose is required to induce ER-
dependent anti-cancer effects as compared with ER-independent one.
For example, tamoxifen, being an ER antagonist, can inhibit cancer cell
growth in ER-dependent manner at 10 nM in ER-sensitive cancer
cells, but at 10 μM in ER-independent manner in ER-negative MDA-
MB-231 cells [43]. However, RA-V inhibited both ER-positive and ER-
negative breast cancer cell migration and invasion at similar doses,
6.25–25 nM, suggesting that RA-V-induced ER-independent pathway
is more important in inhibiting breast cancer cell invasion.
In summary, RA-V can inhibit cell proliferation, cell adhesion, cell
migration and the activity and expression of ECM-associated proteases
in breast cancer cells. RA-V inhibits the expressions of signaling mole-
cules involved in EGFR, PI3K/AKT and NF-κB signaling pathways in
both ER-negative and ER-positive breast cancer cells (Fig. 7E). RA-V is
also shown to induce anti-proliferative, anti-adhesive and anti-
migratory activities in both hormone-positive and hormone-negative
breast cancer cells via PI3K signaling. Although RA-V could reduce ER
binding, its inhibitory effect on cell migration, adhesion and matrix
degradation is ER-independent. These ﬁndings strongly support the
development of RA-V as an anti-metastatic agent and an alternative
therapeutic approach to combat hormone-independent breast cancers.
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